Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer vs Calcium Acetate for Endothelial Dysfunction in CKD
NCT01135615Phase 4Completed
- Sponsor
- Gulhane School of Medicine
- Start
- Jan 2008
- Primary completion
- Apr 2010
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sevelamer carbonate in hyperphosphatemia (2 arms), sponsored by Gulhane School of Medicine. Primary endpoints: Serum Fibroblast Growth Factor 23 Concentration at 8 weeks and Flow-Mediated Dilatation at 8 weeks. Started Jan 2008; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01135615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01135615.